A new survey of 392 high-risk individuals finds that 91% are comfortable using a blood-based test like PancreaSure for early detection, preferring it as a complement to existing imaging.
Published
New data show that PancreaSure detects early-stage pancreatic cancer with 83.3% sensitivity and 91.6% specificity in symptomatic high-risk individuals, supporting the upcoming Medicare application.
Published
Final data from the AFFIRM study confirm PancreaSure achieves 88% sensitivity and 98% specificity, strengthening the clinical evidence base ahead of the U.S. commercial rollout.
Published
On August 6th 2026, CEO Jeff Borcherding and CFO Adam Bäckström presented the report. Watch the webcast for the presentation here.
Published
Comment by: Jeff Borcherding
2025 – The year Immunovia launched PancreaSure and transitioned to a commercial company.
Published
Watch CEO Jeff Borcherding present the company at Aktiespararna’s Life Science theme night from January 26 2026.
Published
